The need for antiemetic drugs, which help prevent or relieve nausea and vomiting, is growing for several reasons. A key factor is the rising incidence of conditions and treatments that cause these ...

On Medindia find the complete list of Antiemetics drugs with their available forms and strength. More information is available on each drug including their price list. We recommend consulting your ...

The best medicine for nausea depends on the underlying cause. It may include over-the-counter (OTC) drugs like Dramamine (dimenhydrinate) and Pepto-Bismol (bismuth ...

Astellas Pharma today announced that the US Food and Drug Administration (FDA) has approved VYLOY (zolbetuximab-clzb) in ...

The novel co-occurrence of JAK2, CALR & MPL mutations in a patient with myelofibrosis challenges previous knowledge that ...

Spanish patients could soon have access to medical cannabis as regulators push forward with a new bill, but its use will be ...

Acute fatty liver of pregnancy (AFLP) is a rare obstetric complication, and despite improvements in recognition and management over recent decades, it still carries a high risk of maternal and fetal ...

drug-free prevention and treatment of nausea and vomiting and be an adjunct to antiemetics in treating post-operative nausea—a good solution. GearBrain is in the process of testing Reliefband, so be ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) in combination ...

Request To Download Free Sample of This Strategic Report @ What is Saudi Arabia Digestive Remedies Market? The Saudi Arabian Digestive Remedies Market is a crucial and evolving sector deeply ...

Plinabulin/Docetaxel Combination Demonstrated Favorable Benefit/Risk Ratio over Docetaxel Alone: Significant Improvement in Overall Survival, Progression Free Survival, and Objective Response, with ...

VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...